Galectin-7-specific monovalent antibodies and uses thereof
US12195541B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 9, 2020 |
| Grant date | Jan 14, 2025 |
| Priority date | — |
| Expiry date | Dec 9, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/164
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Monovalent antibodies such as nanobodies that are specific for galectin-7 are described. These monovalent antibodies are able to interfere with the dimerization of galectin-7, and thus may be used for the treatment of diseases associated with dysregulated galectin-7 expression and/or activity, such as certain types of cancers as well as eye diseases or conditions associated with pathological neovascularization or angiogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.